Journal of New Developments in Molecular Biology

Chengyue Zhang, Celgene Corp
Editorial Board

Chengyue Zhang

Celgene Corp · United States

Editorial leadership for Journal of New Developments in Molecular Biology

Research interests

  • Cancer Biology
  • Molecular Pharmacology

Biography

Publications:

  1. Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.
  2. Epigenetic regulation of Keap1-Nrf2 signaling.
  3. Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane.
  4. Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1.
  5. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential.
  6. Nrf2 knockout attenuates the anti-inflammatory effects of phenethyl isothiocyanate and curcumin.
  7. Blocking of JB6 cell transformation by tanshinone IIA: epigenetic reactivation of Nrf2 antioxidative stress pathway.
  8. Vanadyl bisacetylacetonate protects β cells from palmitate-induced cell death through the unfolded protein response pathway.
  9. MicroRNAs: new players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways.
  10. Flavonoids derived from liquorice suppress murine macrophage activation by up-regulating heme oxygenase-1 independent of Nrf2 activation.
  11. Dietary phytochemicals and cancer chemoprevention: a perspective on oxidative stress, inflammation, and epigenetics.
  12. Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA‐194.
  13. Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1.

Considering JNMB for your work?

This journal is guided by Chengyue Zhang (Celgene Corp) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.

Start your submission

Menu